PASSAGE BIO, INC. Proceeds from Sale of Productive Assets
PASSAGE BIO, INC. (PASG) reported Proceeds from Sale of Productive Assets of $20.00 thousand for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2026-09-03
- PASSAGE BIO, INC. proceeds from sale of productive assets for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PASSAGE BIO, INC. proceeds from sale of productive assets for the quarter ending 2026-03-31 was $20.00K, a 96.58% decline year-over-year.
- PASSAGE BIO, INC. proceeds from sale of productive assets for the quarter ending 2025-06-30 was $585.00K.
- PASSAGE BIO, INC. proceeds from sale of productive assets for the quarter ending 2025-03-31 was $585.00K.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | $20.00K S-4/A · filed 2026-09-03 | |
| 2026-03-31 | $20.00K S-4 · filed 2026-07-21 | ||
| 2025-12-31 | $1.17M S-4/A · filed 2026-09-03 | ||
| 2025-06-30 | $585.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | $1.17M S-4/A · filed 2026-09-03 | |
| 2025-03-31 | $585.00K S-4 · filed 2026-07-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |